Thiazolidinediones in NASH: An odd couple meant to be?

Journal of Clinical Gastroenterology

Volumn 43, Issue 6, 2009, Pages 503-505

  Cusi, Kenneth ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FATTY ACID; GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; BEHAVIOR MODIFICATION; BODY MASS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIET THERAPY; DISEASE EXACERBATION; EDITORIAL; HUMAN; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOPROTEIN METABOLISM; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FIBROSIS; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SPECTROSCOPY; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

CHROMANS; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 67651089650     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181a15e51     Document Type: Editorial

References (16)

1. Cusi K. Thiazolidinediones for the treatment of nonalcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol. 2009. In press.
2. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-525. (Pubitemid 32184944)
3. Neuschwander-Tetri BA, Brunt EM, Kent R, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-g ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
4. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196. (Pubitemid 38461481)
5. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-2307. (Pubitemid 44837778)
6. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-1184.
7. Diabetes Prevention Program. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25:2165-2171. (Pubitemid 41071022)
8. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006; 55:517-522.
9. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Role of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
10. Argo C, Iezzoni J, Al-Osaimi A, et al. Thiazolidinediones in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol. 2009;43:565-568.
11. Cusi K. Evolving concepts in lipotoxicity. The changing face of hepatology: integrating scientific concepts into patient care. 2008; AASLD Postgraduate Course 2008:72-84.
12. Chen J, Mathew M, Cusi K. Prevalence of NAFLD in patients with T2DM [Abstract]. Diabetes. 2009;55(suppl 1).
13. Lutchman G, Apurva M, David EK, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424-429. (Pubitemid 47344777)
14. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for NASH: one year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology. 2008;135:100-110. (Pubitemid 351916703)
15. Ratziu V, Charlotte F, Bernhard C, et al. Long-term efficacy of rosiglitazone in NASH: results of the extension phase of the FLIRT-2 trial. Hepatology. 2008;48(suppl 1): 803A.
16. Elgouhari H, Cesario K, Lopez R, et al. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C Genotype 1 naive patients [Abstract 167]. Hepatology. 2008;48(suppl 1):383A.